HYUNDAI PHARMACEUTICAL CO., LTD
Financials
Valuation Metrics
HYUNDAI PHARMACEUTICAL CO., LTD's Market Cap is ₩3229B. At end of 2025 it was ₩2726B. Ranked #626 of 2,421 in KR market (top 26%), #369 of 781 on KOSPI (top 47%), #65 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 322.88B KRW | KR#626/2,421 Sec#65/231 |
| Revenue | 202.33B KRW | KR#1,028/2,421 Sec#59/231 |
| Net Income | 4.18B KRW | KR#1,267/2,421 Sec#88/231 |
| Total Assets | 224.69B KRW | KR#1,231/2,421 Sec#88/231 |
| Net Assets | 128.05B KRW | KR#1,246/2,421 Sec#97/231 |
| Employees | 401 | KR#603/2,421 Sec#51/231 |
| Value | ||
| P/E | 77.30x | KR#1,464/2,421 Sec#97/231 |
| P/B | 2.52x | KR#2,046/2,421 Sec#159/231 |
| P/S | 1.60x | KR#1,677/2,421 Sec#97/231 |
| EV/EBITDA | 52.14x | KR#1,363/2,421 Sec#87/231 |
| FCF Yield | -1.46% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 3.26% | KR#1,308/2,421 Sec#90/231 |
| ROA | 1.86% | KR#1,246/2,421 Sec#90/231 |
| Op. Margin | 3.46% | KR#1,175/2,421 Sec#86/231 |
| Revenue Growth | 12.04% | KR#803/2,421 Sec#79/231 |
| Financial Health | ||
| Debt Ratio | 75.47% | KR#1,289/2,421 Sec#154/231 |
| Total Debt | 49.55B KRW | KR#1,009/2,421 Sec#71/231 |
| FCF | -4.73B KRW | KR#1,486/2,421 Sec#116/231 |
| Cash | 7.69B KRW | KR#1,834/2,421 Sec#162/231 |
| Current Ratio | 1.69x | KR#1,042/2,421 Sec#117/231 |
| Net Debt/EBITDA | 5.98x | KR#1,083/2,421 Sec#82/231 |
| Dividend | ||
| Div. Yield | 0.30% | KR#1,317/2,421 Sec#83/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | 154.16% | KR#71/2,421 Sec#4/231 |
| 1M Return | 67.89% | KR#33/2,421 Sec#6/231 |
| From 52W High | -36.78% | KR#789/2,421 Sec#52/231 |
| 1Y MDD | -68.41% | KR#1,920/2,421 Sec#163/231 |
| Trading | ||
| Volume | 3,622,589 shares | KR#40/2,421 Sec#3/231 |
| Trading Value | 37.26B KRW | KR#101/2,421 Sec#5/231 |
| Foreign Own. | 0.96% | KR#2,053/2,421 Sec#200/231 |
| Per Share | ||
| EPS | 131 KRW | KR#1,385/2,421 Sec#92/231 |
| BPS | 4,002 KRW | KR#1,668/2,421 Sec#121/231 |
Company Info
Hyundai Pharmaceutical, established in 1965 and listed on the stock market in 1978, is a pharmaceutical and beverage manufacturing and sales company. It produces and supplies both specialized prescription drugs (such as hypertension treatment Tenormin) and over-the-counter drugs (like alopecia treatment Minoxidil Solution and mosquito bite relief Burmuli) to hospitals, clinics, and pharmacies nationwide. The company is currently conducting Phase 2b clinical trials for HDNO-1605, an innovative new drug for diabetes, and actively seeking improved new drugs to enhance medication adherence in the cardiovascular sector. Hyundai Pharmaceutical is headquartered in Cheonan-si, Chungcheongnam-do.